From endocrine to rheumatism: Do gut hormones play roles in rheumatoid arthritis?

Rheumatology (United Kingdom)

Volumn 53, Issue 2, 2014, Pages 205-212

  Chen, Chih Yen ^a,b   Tsai, Chang Youh ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Energy balance; Gut hormones; Inflammation; Rheumatoid arthritis

Indexed keywords

ACYL GHRELIN; DES ACYL GHRELIN; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APPETITE; BODY COMPOSITION; BODY MASS; BONE REMODELING; CATABOLISM; CHRONIC INFLAMMATION; ENDOCRINE SYSTEM; ENERGY EXPENDITURE; HORMONE ACTION; HORMONE RELEASE; HUMAN; IMMUNE SYSTEM; MUSCULOSKELETAL SYSTEM; NUTRITION; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS;

ENERGY BALANCE; GUT HORMONES; INFLAMMATION; RHEUMATOID ARTHRITIS;

APPETITE; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; ENERGY METABOLISM; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFLAMMATION; PEPTIDE YY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892516423     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket255     Document Type: Review

References (79)

1. Geiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des 2011;17:3141-54.
2. Marcora SM, Chester KR, Mittal G et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006;84:1463-72.
3. Engvall IL, Elkan AC, Tengstrand B et al. Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulinlike growth factor. Scand J Rheumatol 2008;37:321-8.
4. Reid MB, Li YP. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2001;2:269-72.
5. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83: 735-43.
6. Bingham CO III, Ince A, Haraoui B et al. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr Med Res Opin 2009;25:1131-42.
7. Su KY, Lee HT, Chou CT et al. Improvement of active rheumatoid arthritis after etanercept injection: a singlecenter experience. J Chin Med Assoc 2009;72:581-7.
8. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology 2007;132:2116-30.
9. Kojima M, Hosoda H, Date Y et al. Ghrelin is a growthhormone-releasing acylated peptide from stomach. Nature 1999;402:656-60.
10. Hosoda H, Kojima M, Matsuo H et al. Purification and characterization of rat des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. J Biol Chem 2000;75:1995-2000.
11. Chen CY, Tsai CY, Lee WJ et al. Intracerebroventricular O-n-octanoylated ghrelin and its splice variant-induced feeding is blocked by insulin, independent of obestatin or CRF receptor, in satiated rats. Nutrition 2012;28: 812-20.
12. Howard AD, Feighner SD, Cully DF et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974-7.
13. Yang J, Brown MS, Liang G et al. Identification of the acyltransferase that octanoylates ghrelin, an appetitestimulating peptide hormone. Cell 2008;132:387-96.
14. Hattori N, Saito T, Yagyu T et al. GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab 2001;86:4284-91.
15. Dixit VD, Schaffer EM, Pyle RS et al. Ghrelin inhibits leptinand activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114:57-66.
16. Rodríuez A, Gómez-Ambrosi J, Catalán V et al. The ghrelin O-acyltransferase-ghrelin system reduces TNF-ainduced apoptosis and autophagy in human visceral adipocytes. Diabetologia 2012;55:3038-50.
17. Chen CY, Tsai CY. Ghrelin and motilin in the gastrointestinal system. Curr Pharm Des 2012;18:4755-65.
18. Lee WJ, Chen CY, Chong K et al. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 2011;7:683-90.
19. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407:908-13.
20. Tschöp M, Weyer C, Tataranni PA et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50: 707-9.
21. Huda MS, Dovey T, Wong SP et al. Ghrelin restores 'leantype' hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects. Int J Obes 2009;33:317-25.
22. Zakhari JS, Zorrilla EP, Zhou B et al. Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. Mol Pharm 2012;9: 281-9.
23. Montoya-Flores D, Mora O, Tamariz E et al. Ghrelin stimulates myogenic differentiation in a mouse muscle satellite cell line and in primary cultures of bovine myoblasts. J Anim Physiol Anim Nutr 2012;96: 725-38.
24. Koshinaka K, Toshinai K, Mohammad A et al. Therapeutic potential of ghrelin treatment for unloading-induced muscle atrophy in mice. Biochem Biophys Res Commun 2011;412:296-301.
25. Sugiyama M, Yamaki A, Furuya M et al. Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice. Regul Pept 2012;178:21-8.
26. Napoli N, Pedone C, Pozzilli P et al. Effect of ghrelin on bone mass density: the InChianti study. Bone 2011;49: 257-63.
27. van der Velde M, van der Eerden BC, Sun Y et al. An age-dependent interaction with leptin unmasks ghrelin's bone-protective effects. Endocrinology 2012;153: 3593-602.
28. Kang K, Schmahl J, Lee JM et al. Mouse ghrelin-O-acyltransferase (GOAT) plays a critical role in bile acid reabsorption. FASEB J 2012;26:259-71.
29. Cheng KC, Li YX, Cheng JT. The use of herbal medicine in cancer-related anorexia/cachexia treatment around the world. Curr Pharm Des 2012;18:4819-26.
30. Otero M, Nogueiras R, Lago F et al. Chronic inflammation modulates ghrelin levels in humans and rats. Rheumatology 2004;43:306-10.
31. Koca SS, Ozgen M, Aydin S et al. Ghrelin and obestatin levels in rheumatoid arthritis. Inflammation 2008;31: 329-35.
32. Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A et al. Antitumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis 2008;67:1644-6.
33. Ferraz-Amaro I, Arce-Franco M, Muñiz J et al. Systemic blockade of TNF-a does not improve insulin resistance in humans. Horm Metab Res 2011;43:801-8.
34. Magiera M, Kopec-Medrek M, Widuchowska M et al. Serum ghrelin in female patients with rheumatoid arthritis during treatment with infliximab. Rheumatol Int 2013;33: 1611-3.
35. Chen CY, Tsai CY, Lee PC et al. Long-term etanercept therapy favors weight gain and ameliorates cachexia in rheumatoid arthritis patients: roles of gut hormones and leptin. Curr Pharm Des 2013;19:1956-64.
36. Chen CY, Asakawa A, Fujimiya M et al. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 2009;61:430-81.
37. Broglio F, Gottero C, Prodam F et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004;89:3062-5.
38. Garcia JM, Garcia-Touza M, Hijazi RA et al. Active ghrelin levels and active to total ghrelin ratio in cancerinduced cachexia. J Clin Endocrinol Metab 2005;90: 2920-6.
39. Yoshimoto A, Mori K, Sugawara A et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 2002;13:2748-52.
40. Delhanty PJ, Neggers SJ, van der Lely AJ. Mechanisms in endocrinology. Ghrelin: the differences between acyl-and des-acyl ghrelin. Eur J Endocrinol 2012;167: 601-8.
41. Rodríguez A, Gómez-Ambrosi J, Catalán V et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes 2009;33:541-52.
42. Kumar R, Salehi A, Rehfeld JF et al. Proghrelin peptides: desacyl ghrelin is a powerful inhibitor of acylated ghrelin, likely to impair physiological effects of acyl ghrelin but not of obestatin: A study of pancreatic polypeptide secretion from mouse islets. Regul Pept 2010;164:65-70.
43. Lear PV, Iglesias MJ, Feijóo-Bandín S et al. Des-acyl ghrelin has specific binding sites and different metabolic effects from ghrelin in cardiomyocytes. Endocrinology 2010;151:3286-98.
44. Estep M, Abawi M, Jarrar M et al. Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg 2011;21: 1750-7.
45. Delhanty PJ, Sun Y, Visser JA et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS One 2010;5:e11749.
46. Sheriff S, Kadeer N, Joshi R et al. Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats. Mol Cell Endocrinol 2012;351: 286-95.
47. Chen CY, Inui A, Asakawa A et al. Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology 2005;129:8-25.
48. Matsuda K, Miura T, Kaiya H et al. Regulation of food intake by acyl and des-acyl ghrelins in the goldfish. Peptides 2006;27:2321-5.
49. Cederberg H, Rajala U, Koivisto VM et al. Unacylated ghrelin is associated with changes in body composition and body fat distribution during long-term exercise intervention. Eur J Endocrinol 2011;165:243-8.
50. Chen CY, Fujimiya M, Laviano A et al. Modulation of ingestive behavior and gastrointestinal motility by ghrelin in diabetic animals and humans. J Chin Med Assoc 2010;73: 225-9.
51. Cho YM, Kieffer TJ. K-cells and glucose-dependent insulinotropic polypeptide in health and disease. Vitam Horm 2010;84:111-50.
52. Paschetta E, Hvalryg M, Musso G. Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders. Obes Rev 2011;12:813-28.
53. Neumiller JJ. Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovasc Hematol Agents Med Chem 2012;10:276-88.
54. Salehi M, Aulinger B, D'Alessio DA. Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. Diabetes 2012;61:2728-33.
55. Eckel RH, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 1979;28:1141-2.
56. Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 2007;282:34139-47.
57. Asmar M, Simonsen L, Madsbad S et al. Glucosedependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 2010;59:2160-3.
58. Xie D, Zhong Q, Ding KH et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 2007;40:1352-60.
59. Ding KH, Shi XM, Zhong Q et al. Impact of glucosedependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res 2008;23:536-43.
60. Daousi C, Wilding JP, Aditya S et al. Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin Endocrinol 2009;71:195-201.
61. Edholm T, Degerblad M, Grybäck P et al. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil 2010;22:1191-200.
62. Nie Y, Ma RC, Chan JC et al. Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes. FASEB J 2012;26:2383-93.
63. Timper K, Grisouard J, Sauter NS et al. Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis and insulin resistance in human adipocytes. Am J Physiol Endocrinol Metab 2013;304:E1-13.
64. Shiraki A, Oyama J, Komoda H et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-a-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012;221:375-82.
65. Lee YS, Park MS, Choung JS et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 2012;55:2456-68.
66. Parkinson JR, Chaudhri OB, Kuo YT et al. Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage 2009;44:1022-31.
67. Pannacciulli N, Bunt JC, Koska J et al. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 2006;84:556-60.
68. Rosenstock J, Shenouda SK, Bergenstal RM et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012;35:955-8.
69. Shin J, Chang JS, Kim HS et al. Effects of a 6-month exenatide therapy on HbA1c and weight in Korean patients with type 2 diabetes: a retrospective cohort study. Diabetes Metab J 2012;36:364-70.
70. Field BC, Wren AM, Peters V et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010;59: 1635-9.
71. Vermeulen MA, Richir MC, Garretsen MK et al. Gastric emptying, glucose metabolism and gut hormones: evaluation of a common preoperative carbohydrate beverage. Nutrition 2011;27:897-903.
72. Talsania T, Anini Y, Siu S et al. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005;146:3748-56.
73. Vona-Davis L, Yu A, Magabo K et al. Peptide YY attenuates transcription factor activity in tumor necrosis factor-alpha-induced pancreatitis. J Am Coll Surg 2004;199: 87-95.
74. Witte AB, Grybäck P, Holst JJ et al. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept 2009;158:57-62.
75. Nguyen NQ, Fraser RJ, Bryant LK et al. The relationship between gastric emptying, plasma cholecystokinin, and peptide YY in critically ill patients. Crit Care 2007;11: R132.
76. Doucet E, Laviolette M, Imbeault P et al. Total peptide YY is a correlate of postprandial energy expenditure but not of appetite or energy intake in healthy women. Metabolism 2008;57:1458-64.
77. Straub RH, Pongratz G, Cutolo M et al. Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Rheum 2008;58: 976-84.
78. Cutolo M, Sulli A, Capellino S et al. Anti-TNF and sex hormones. Ann N Y Acad Sci 2006;1069: 391-400.
79. Yajnik CS, Yudkin JS. The Y-Y paradox. Lancet 2004;363: 163.